Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy: A network meta-analysis

Table 3 The surface under the cumulative ranking curve for outcomes

	Clinical effective rate (%)	RBC (%)	Hb (%)	SF (%)	SI (%)	Incidence of adverse pregnancy outcomes (%)	Adverse events (%)
SXB + OI	62.2	49.5	33.2	40.9	33.3	60.6	47.4
SXN + OI	41.4	98.7	96	46.8	81.9	75.3	85.3
YQWX + OI	59.1	71.9	54.9	92.3	51.4	43.3	45.1
JPSX + OI	66	41.7	52.9	35.6	71	77.1	52.2
YQBX + OI	40.5	52.5	81.7	51.1	65.5	41.4	94
FFHY + OI	80.2	32.1	30.1	82.2	42	-	6.3
OI	0.5	3.7	1.4	1	4.8	2.4	19.7

OI: Oral iron; SXB: Shengxuebao Mixture; SXN: Shengxianning Tablet; YQWX: Yiqi Weixue Chinese patent medicines; JPSX: Jianpi Shengxue Chinese patent medicines; YQBX: Yiqi Buxue Tablets; FFHY: Compound Hongyi Buxue Oral Liquid; RBC: Red blood cells counts; Hb: Hemoglobin; SF: Serum ferritin; SI: Serum iron.